MEK inhibitor resistance mechanisms and recent developments in combination trials

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The mitogen-activated protein kinase (MAPK) pathway, also known as the RAS-RAF-MEK-ERK pathway, is crucial for cell functions.
• This pathway is frequently dysregulated in cancers, often due to mutations in RAS or RAF genes (e.g., KRAS, BRAF), leading to uncontrolled cell growth.
• Dysregulation drives sustained cell proliferation and tumor growth, making it a key target in cancer therapy.

Purpose of the Study:

• To summarize recent advancements in MEK inhibitors (MEKi) for cancer treatment.
• To elucidate the mechanisms of adaptive resistance that limit MEKi efficacy.
• To explore potential strategies to overcome adaptive resistance to MEKi.

Main Methods:

• Review of in vitro and clinical studies on MEK inhibitors.
• Analysis of molecular mechanisms underlying adaptive resistance to MEKi.
• Exploration of therapeutic strategies to counteract resistance.

Main Results:

• MEKi have emerged as a first-line treatment for certain cancers, demonstrating significant promise.
• However, not all patients respond to MEKi, and acquired resistance is a common challenge.
• Understanding adaptive resistance mechanisms is critical for improving treatment outcomes.

Conclusions:

• MEKi represent a significant therapeutic advance in oncology.
• Adaptive resistance mechanisms pose a major hurdle to long-term MEKi effectiveness.
• Developing strategies to overcome resistance is essential for enhancing patient response and survival.